Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sagar Lonial

Showing results (241-250 of 440) with videos related to

Pageof 44
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2008
Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX studyAsher Chanan-Khan, Pieter Sonneveld, Michael W Schuster, et al.
Blood Cancer Journal|January 6, 2019
Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I StudyJonathan L Kaufman, Roberto Mina, Andrzej J Jakubowiak, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 24, 2021
Daratumumab With Cetrelimab, an Anti-PD-1 Monoclonal Antibody, in Relapsed/Refractory Multiple MyelomaYael C Cohen, Albert Oriol, Ka Lung Wu, et al.
Transfusion|April 16, 2011
Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kineticsJie Li, Ellie Hamilton, Louette Vaughn, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 8, 2013
Vinorelbine, paclitaxel, etoposide, cisplatin, and cytarabine (VTEPA) is an effective second salvage therapy for relapsed/refractory Hodgkin lymphomaRajni Sinha, Pareen J Shenoy, Nassoma King, et al.
British Journal of Haematology|April 25, 2007
Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myelomaPaul G Richardson, Pieter Sonneveld, Michael W Schuster, et al.
The Lancet. Haematology|May 26, 2024
Pembrolizumab and low-dose, single-fraction radiotherapy for patients with relapsed or refractory multiple myeloma: a prospective, single-centre, single-group, open-label, phase 2 pilot trial in the USAMohammad K Khan, Tahseen H Nasti, Joshua Y Qian, et al.
Blood|June 13, 2014
Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patientsPaul G Richardson, Rachid Baz, Michael Wang, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 11, 2014
Pharmacoeconomic analysis of palifermin to prevent mucositis among patients undergoing autologous hematopoietic stem cell transplantationAjay K Nooka, Heather R Johnson, Jonathan L Kaufman, et al.
Nature Medicine|September 27, 2024
SARS-CoV-2-specific plasma cells are not durably established in the bone marrow long-lived compartment after mRNA vaccinationDoan C Nguyen, Ian T Hentenaar, Andrea Morrison-Porter, et al.
Pageof 44

Showing results (241-250 of 440) with videos related to

Sort By:
Pageof 44
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2008
Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX studyAsher Chanan-Khan, Pieter Sonneveld, Michael W Schuster, et al.
Blood Cancer Journal|January 6, 2019
Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I StudyJonathan L Kaufman, Roberto Mina, Andrzej J Jakubowiak, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 24, 2021
Daratumumab With Cetrelimab, an Anti-PD-1 Monoclonal Antibody, in Relapsed/Refractory Multiple MyelomaYael C Cohen, Albert Oriol, Ka Lung Wu, et al.
Transfusion|April 16, 2011
Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kineticsJie Li, Ellie Hamilton, Louette Vaughn, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 8, 2013
Vinorelbine, paclitaxel, etoposide, cisplatin, and cytarabine (VTEPA) is an effective second salvage therapy for relapsed/refractory Hodgkin lymphomaRajni Sinha, Pareen J Shenoy, Nassoma King, et al.
British Journal of Haematology|April 25, 2007
Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myelomaPaul G Richardson, Pieter Sonneveld, Michael W Schuster, et al.
The Lancet. Haematology|May 26, 2024
Pembrolizumab and low-dose, single-fraction radiotherapy for patients with relapsed or refractory multiple myeloma: a prospective, single-centre, single-group, open-label, phase 2 pilot trial in the USAMohammad K Khan, Tahseen H Nasti, Joshua Y Qian, et al.
Blood|June 13, 2014
Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patientsPaul G Richardson, Rachid Baz, Michael Wang, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 11, 2014
Pharmacoeconomic analysis of palifermin to prevent mucositis among patients undergoing autologous hematopoietic stem cell transplantationAjay K Nooka, Heather R Johnson, Jonathan L Kaufman, et al.
Nature Medicine|September 27, 2024
SARS-CoV-2-specific plasma cells are not durably established in the bone marrow long-lived compartment after mRNA vaccinationDoan C Nguyen, Ian T Hentenaar, Andrea Morrison-Porter, et al.
Pageof 44